Login to Your Account



Intercell's Adjuvant Patch Fails to Boost Pandemic Flu Vaccine

By Cormac Sheridan


Wednesday, July 7, 2010
A faulty hemagglutinin inhibition assay may be the reason underlying the failure of a Phase II clinical trial of Intercell AG's investigational Vaccine Enhancement Patch (VEP) for H5N1 influenza. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription